Low-dose CD7 chimeric antigen receptor T cells for relapsed/refractory T-cell lymphomas: a single-arm, open-label, phase Ia/Ib study

Relapsed or refractory T-cell lymphomas (r/r TCLs), including T-lymphoblastic lymphoma (T-LBL) and mature subtypes, have poor outcomes, with fewer than 30% of patients achieving long-term survival despite intensive therapies [ 1 , 2 ]. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is often recommended at first relapse [ 3 ]; however, many patients fail to achieve sufficient remission to undergo transplantation, particularly after prior allo-HSCT, which portends a dismal prognosis [ 1 ].